Targeted drug achieves 43% response rate in KRAS-mutated lung cancer
BOSTON - Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation ...
Tag: KRASmutated
-
Experts optimistic about converting coal plants to production of clean geothermal energy
-
New flavored nicotine gums, lozenges, and gummies rank second among nicotine products used by U.S. teens
-
The North American Menopause Society releases its 2022 Hormone Therapy Position Statement
-
Coarse sea spray keeps lightning strikes away
-
Robotic motion in curved space defies standard laws of physics
-
Fatigue, headache among top lingering symptoms months after COVID